Production of proteins of interest in non-sporulating bacterial strains

By using a strong promoter-controlled expression cassette in non-spore-producing Bacillus bacteria to wrap or anchor the target protein, the complex protein stability and toxicity problems in bacterial production are solved, and efficient and safe protein production is achieved.

CN119095969APending Publication Date: 2024-12-06INSTITUT NATIONAL DE LA RECHERCHE POUR L AGRICULTURE, L ALIMENTATION ET L ENVIRONNEMENT +2
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202380036667.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2022-05-02
Filing Date
2023-04-26
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

Prior art When using recombinant bacteria to produce proteins of interest, especially complex structural proteins such as antibodies or coagulation factors, it is difficult to stabilize in the body and have low activity, and the produced proteins are toxic to bacterial cells, resulting in production efficiency and safety issues.

Method used

Using non-spore-producing Bacillus bacterial strains, express and encapsulate the protein of interest in the bacterial balloon or anchor to the cell surface by using a strong promoter in the stationary phase, using specific regulators such as CodY, AbrB, SinR, PlcR and NprR regulate strong promoters, ensuring high protein expression and stability.

Benefits of technology

High yield production of toxic or unstable target proteins is achieved, ensuring that the protein is not degraded by bacterial cells, simplifying the recycling and purification process, reducing production costs, and improving the stability and activity of the protein.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005102998400000082
    Figure BDA0005102998400000082
  • Figure BDA0005102998400000085
    Figure BDA0005102998400000085
  • Figure BDA0005102998400000087
    Figure BDA0005102998400000087
Patent Text Reader

Abstract

The present invention relates to a novel system for producing a protein of interest, consisting of a non-sporulating strain of the genus Bacillus transformed with a plasmid comprising an expression cassette of the protein of interest under the control of a strong promoter having activity in a stationary phase. The protein of interest thus produced is present in the bacterial balloon or anchored to the surface of the bacteria.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to a novel system for producing a protein of interest, which consists of a non-sporulating bacterial strain of the genus Bacillus, which is transformed with a plasmid containing an expression cassette for the protein of interest under the control of a strong promoter active in stationary phase. The protein of interest thus produced is present in a bacterial spherule composed of a bacterial membrane or anchored to the bacterial surface.

[0002] The use of recombinant bacteria to produce target proteins (such as insulin and growth hormone) has long been known and widely practiced, but it has also shown its limitations. In fact, bacteria are unable to produce proteins with complex structures (such as antibodies or coagulation factors). In order to be stable and active in vivo and therefore effective in humans, these proteins must undergo multiple post-translational modifications.

[0003] The heterologous proteins of interest are also toxic to the bacterial cells that produce them. Vincent Ecochard et al., in their Professional Master's Degree "Techniques et Stratégie en Biologie Moléculaire", October 2011, http: / / www.m2p-egpr.ups-tlse.fr / Documents%20archives / Cours / Cours%20partie%202.pdf, detail solutions that can be provided to produce such proteins in bacterial systems. However, it is not easy to determine the best solution in relation to the protein to be produced. The authors do conclude that the last solution and the best approach is to use an in vitro translation system.

[0004] Rosano et al., "Recombinant protein expression in Escherichia coli: advances and challenges", Front. Microbiol., April 17, 2014, https: / / doi.org / 10.3389 / fmicb.2014.00172, pointed out that only a few strains of Escherichia coli are able to produce toxic proteins, but the production levels of these proteins are very low. Solutions can be provided by using different promoters to secrete proteins outside the bacterial cell or to the periplasm.

[0005] Therefore, there is a need for a bacterial system that is easy to implement and has high yields for producing target proteins, especially for the production of target proteins that can be toxic.

[0006] Bacillus thuringiensis (Bt) is a Gram-positive sporulating bacterium that produces large amounts of insecticidal proteins (Cry and Cyt proteins). When certain Bt sporulation genes (such as spoOA, sigE or sigF) are no longer expressed, or when their products are no longer functional after mutation, the bacteria cannot start sporulation and remain arrested in the stationary phase. The consequence of the inactivation of sporulation genes is that bacterial proliferation stops and the bacteria cannot survive.

[0007] The inventors have shown that non-spore-forming Bt strains lead to the formation of bacterial spherules. Surprisingly, they have also shown that in such non-spore-forming strains, the production of target proteins can be obtained by placing the target gene under the control of a promoter that is specifically activated during the stationary phase. Thus, the target protein is produced during the stationary phase and remains encapsulated in the bacterial spherules. The inventors have also shown that these proteins are produced in large quantities, and the positioning of these proteins in the bacterial spherules protects them from degradation and greatly facilitates the recovery of these proteins and the purification of these proteins. According to specific embodiments, the target proteins can also be expressed so that these target proteins anchor themselves to the surface of the bacterial cell.

[0008] This novel system thus enables the production of proteins of interest, in particular proteins that are unstable or toxic to the producing bacterial cells, which are non-sporulating and non-viable.

[0009] Therefore, the present invention relates to a non-spore-forming bacterial strain of the genus Bacillus, the bacterial strain comprising a recombinant plasmid comprising an expression cassette consisting of:

[0010] (i) a strong promoter that is active in stationary phase and is regulated by a regulator selected from the group consisting of CodY, AbrB, SinR, PlcR and NprR; and

[0011] (ii) The sequence of the gene encoding the protein of interest.

[0012] Preferably, the bacterial strain is selected from Bacillus thuringiensis, Bacillus cereus, Bacillus weihenstephanensis, and more preferably, the bacterial strain is a strain of Bacillus thuringiensis. It is also possible to use strains of Bacillus subtilis, Bacillus megaterium, Bacillus brevis, as long as they are previously transformed to express the papR and plcR genes that activate the PpapR and PplcR promoters, respectively, and / or to express the npnR and nprX genes that activate the PnprA promoter.

[0013] Preferably, the bacterial strain used is a Bt kurstaki HD-73 or Bt 407 strain. According to the present invention, the bacterial strain is a non-spore-forming strain. In fact, the advantage of non-spore-forming strains is that they do not undergo cell lysis, so the target protein produced is preserved in the produced bacteria and is protected from degradation by extracellular proteases.

[0014] In order to inhibit the sporulation activity of a strain of the genus Bacillus, any gene necessary for sporulation can be inactivated, such as the gene involved in the expression of the Spo0A transcriptional regulator responsible for the initiation of sporulation, or the gene involved in the expression of the sigma factor of sporulation SigE, SigF, SigH and SigK; preferably, the inactivated gene is spo0A or sigE. The inactivation of these genes can be obtained by interrupting or modifying the coding sequence, or by deleting all or part of the gene. The deletion was obtained by double crossing over between adjacent regions located upstream and downstream of the gene, using a plasmid whose replication is sensitive to temperature, such as plasmid pRN5101 (Lereclus et al., Expansion of insecticidal host range of Bacillus thuringiensis by in vivo genetic recombination. Biotechnology (NY) 10:418-421, 1992) or pMAD (Arnaud et al., New vector for efficient allelic replacement in naturally nontransformable, low-GC-content, gram-positive bacteria. Appl Environ Microbiol 70:6887-6891, 2004) and using the protocols described in these articles. Deletion of the Spo0A gene (named ASpo0A) has a very early effect when the bacteria enter the stationary phase, in particular preventing the bacteria from participating in the sporulation process (Lereclus et al., Overproduction of encapsulated insecticidal crystal proteins in a Bacillus thuringiensis Spo0A mutant. Biotechnology (NY) 13: 67-71, 1995). Deletion of the sigE gene (named ΔsigE) has a later effect, preventing the progress of the sporulation process (Bravo et al., Analysis of crylAaexpression in sigE and sigK mutants of Bacillus thuringiensis. Mol Gen Genet 250: 734-741, 1996). In both cases, the bacteria no longer proliferate, die and contain almost only the protein of interest.

[0015] Preferably, the strain used is Bt kurstaki HD-73Δspo0A or Bt 407ΔsigE.

[0016] The recombinant plasmid that can be used according to the present invention generally comprises an origin of replication and at least one selection system, and this selection system is made up of one or more genes (for example, antibiotic resistance genes) that allow selection of transformed bacteria. Any plasmid that is compatible with the bacterial host used can be realized, preferably a plasmid with a high copy number.

[0017] Suitable plasmids according to the invention are plasmids which allow expression in bacteria of the genus Bacillus.

[0018] Preferably, the plasmid used is one with high separation and / or structural stability.

[0019] The concept of segregation stability means that the plasmid will not be lost in the generation; in other words, it is stably maintained in the bacterial cell and transmitted to the daughter cells. The segregation stability of the plasmid pHT1030 has been demonstrated (Lereclus et al., 1992. spbAlocus ensures the segregational stability of pHT1030, a novel type of Gram-positive replicon. Mol. Microbiol. 7: 35-46). This stability is due to the presence of the spbA gene, which is also present in plasmids derived from pHT1030 (such as pHT3101, pHT304, pHT315 and pHT370) (Arantes et al., 1991. Construction of cloning vectors for Bacillus thuringiensis. Gene 108: 115-119). The segregation stability of plasmid pBC16 and its derivatives was also determined (Lereclus et al., 1992. spbA locus ensures the segregational stability of pHT1030, a novel type of Gram-positive replicon. Mol. Microbiol. 7:35-46).

[0020] Structural stability is defined as non-intramolecular recombination of the plasmid. The structural stability of plasmid PHT1030 and its derivatives was demonstrated because they can carry large foreign DNA fragments (>10 kb) without undergoing molecular rearrangement (Lereclus et al., 1989. Transformation and expression of a cloned delta-endotoxingene in Bacillus thuringiensis. FEMS Microbiol. Lett. 60: 211-217).

[0021] Preferably, they are high copy number plasmids, in particular derived from plasmid pHT1030 (such as pH3101, pHT304, pHT315 and pHT370, preferably pH315) or derived from plasmids pBC16, pE194 or pC194, or are low copy number plasmids (such as pHT73, Bt kurstaki HD-73 or pBMB299 strains or Bt kurstaki HD1 strains The persistence plasmid).

[0022] According to the present invention, the expression cassette inserted into the plasmid comprises at least a strong promoter and the sequence of the gene encoding the protein of interest.

[0023] A strong promoter is a promoter that allows strong transcription of one or more genes controlled by it. A strong promoter can come from a host cell for expressing a target protein, or it can be an exogenous promoter. A strong promoter is preferably a promoter that is activated at the beginning of the stationary phase and remains functional in a large part of this physiological state. Typically, according to the calculations described in Perchat et al. ("A cell-cell communication System regulates protease production duringsporulation in bacteria of the Bacillus cereus group", Molecular Biology, Vol. 82, 3, p. 619-633, 2011), the expression of the promoter is assessed using the activity of R-galactosidase (AS, units / mg protein): AS = (A 420 x 1500000) / (T x V x C).

[0024] A 420 : Absorbance at 420nm

[0025] T: reaction time (min)

[0026] V: volume of crude extract (μL)

[0027] C: Protein concentration (μg / mL)

[0028] Using this formula, a promoter is considered highly expressed when the AS is greater than 500 U / mg protein.

[0029] According to a first embodiment of the present invention, the strong promoter is regulated by a regulator selected from PlcR and NprR. The strong promoter is preferably selected from PpapR (SEQ.ID.NO: 1), PplcB (SEQ.ID.NO: 2), PnprA (SEQ.ID.NO: 3) and PnprR (SEQ.ID.NO: 4).

[0030] According to a second embodiment of the invention, the strong promoter is regulated by a regulator selected from CodY, AbrB and SinR, and even more preferably, the strong promoter is selected from PoppA (SEQ.ID.NO.5), PnppC (SEQ.ID.NO.6), PinhA1 (SEQ.ID.NO.7) and PcolY (SEQ.ID.NO.8).

[0031] Preferably, the regulator is CodY and the strong promoter is PoppA or PnppC.

[0032] The expression cassette according to the present invention can also comprise:

[0033] - a stabilizing sequence of mRNA, which is located downstream of the promoter and upstream of the gene sequence encoding the heterologous protein; preferably, it is the STAB-SD of the sequence SEQ ID NO.9; preferably, the STAB-SD sequence is located downstream of transcription +1 and upstream of the ribosome binding site (RBS) at a position comprised between about 100 nucleotides and 500 nucleotides, preferably between 100 nucleotides and 300 nucleotides, more preferably between 100 nucleotides and 150 nucleotides; and / or

[0034] - The terminator sequence of the cry1Ac gene (named Tcry1Ac), for example, a sequence having at least 90% identity with SEQ ID NO. 10, preferably, it is SEQ ID NO. 10; this sequence is cloned downstream of the gene encoding the target protein.

[0035] However, the choice of these sequences should not be considered limiting, as one skilled in the art can replace these sequences with functionally equivalent sequences.

[0036] The term "target protein" means an endogenous protein or a protein not naturally expressed by the bacterial strain according to the invention, also referred to as a heterologous protein. Preferably, the target protein is a cytotoxic protein or an industrial target protein naturally expressed by a strain of the genus Bacillus, such as an enzyme (e.g., a protease, a lipase, an amylase), a hormone, an antigen (e.g., a protein that can be used as an immunogen, a polypeptide or for therapeutic use); thus, the target protein can be used in crop protection, vector control, commercial production of enzymes and the pharmaceutical industry, in particular for the production of vaccines.

[0037] The expression cassette according to the invention leads to the expression and subsequent accumulation of the protein of interest in the bacterial spheroid, or to their anchoring to the surface of the bacteria. Its use is particularly suitable for the production of proteins that are unstable or toxic to the producing strain.

[0038] As shown in the experimental part, the construction of the expression cassette according to the invention and its incorporation into a plasmid is performed by molecular biology techniques well known to the person skilled in the art.

[0039] The plasmid according to the present invention can be introduced into the host bacteria according to techniques known to those skilled in the art; in particular, the transformation of the host bacteria can be carried out by electroporation (Lereclus et al., 1989) or by heteroconjugation (Tieu-Cuot et al., 1987). It is also possible to introduce the expression cassette containing the target gene into the bacterial chromosome or the retention plasmid by homologous recombination (Lereclus et al., 1992).

[0040] The present invention also relates to a method for producing a target protein, comprising the following steps:

[0041] a- preparing the bacterial strain according to the present invention;

[0042] b- cultivating said bacterial strain in stationary phase; and

[0043] c-Optionally, purify the protein of interest.

[0044] The cultivation of the bacterial strain is carried out on a medium comprising appropriate concentrations of at least one nitrogen source and glucose, preferably at a temperature comprised between 25°C and 35°C, preferably at 30°C; for example, the medium is LB base.

[0045] Purification of the protein of interest can be performed by centrifugation; in addition, it can be performed using methods of size exclusion chromatography, ion exchange chromatography or even affinity chromatography.

[0046] According to a specific embodiment, a gene encoding an exporter domain (such as a signal peptide) or an anchoring protein (such as LysM (SEQ. ID NO. 11), SLH (SEQ ID NO. 12) or LPXTG (Navarre et al., Microbiol Mol Biol Rev 63(1): 174-229. DOI: 10.1128, 1999)) of a protein on the surface of the bacteria is cloned in cis with the gene encoding the protein of interest.

[0047] Thus, an expression cassette according to the invention can comprise:

[0048] (i) a strong promoter active in the stationary phase, the strong promoter selected from the group consisting of PpapR, PpIcB, PnprA, PnprR, PoppA, PnppC, PinhA1 and PcalY, and preferably selected from the group consisting of PoppA and PnppC;

[0049] (ii) optionally, a gene sequence encoding an exportin or an anchoring protein;

[0050] (iii) the sequence of the gene encoding the target protein;

[0051] and, optionally, an mRNA stabilizing sequence, preferably STAB-SD, and / or a terminator sequence of the cry1Ac, Tcry1Ac gene;

[0052] or

[0053] (i) a strong promoter active in the stationary phase, the strong promoter selected from the group consisting of PpapR, PpIcB, PnprA, PnprR, PoppA, PnppC, PinhA1 and PcalY, and preferably selected from the group consisting of PoppA and PnppC;

[0054] (ii) optionally, a gene sequence encoding an exportin or an anchoring protein;

[0055] (iii) the sequence of the gene encoding the target protein;

[0056] and a stabilizing sequence for mRNA, preferably STAB-SD;

[0057] or

[0058] (i) a strong promoter active in the stationary phase, the strong promoter selected from the group consisting of PpapR, PpIcB, PnprA, PnprR, PoppA, PnppC, PinhA1 and PcalY, and preferably selected from the group consisting of PoppA and PnppC;

[0059] (ii) optionally, a gene sequence encoding an exportin or an anchoring protein;

[0060] (iii) the sequence of the gene encoding the target protein;

[0061] and the terminator sequences of cry1Ac and Tcry1Ac genes;

[0062] Or even

[0063] (i) a strong promoter active in the stationary phase, the strong promoter selected from the group consisting of PpapR, PpIcB, PnprA, PnprR, PoppA, PnppC, PinhA1 and PcalY, and preferably selected from the group consisting of PoppA and PnppC;

[0064] (ii) optionally, a gene sequence encoding an exportin or an anchoring protein;

[0065] (iii) the sequence of the gene encoding the target protein;

[0066] And a stabilizing sequence of mRNA, preferably STAB-SD, and the terminator sequence of cry1Ac and Tcry1Ac genes.

[0067] According to a specific embodiment, the strain used is a bacterium of the genus Bacillus ΔspoOA, preferably Bt Δspo0A, more preferably Bt HD73 Δspo0A, and the expression cassette comprises:

[0068] (i) a strong promoter active in the stationary phase, the strong promoter selected from the group consisting of PpapR, PpIcB, PoppA, PnprR, PnppC and PnprA, and preferably selected from the group consisting of PoppA and PnppC;

[0069] (ii) optionally, a gene sequence encoding an exportin or an anchoring protein;

[0070] (iii) the sequence of the gene encoding the target protein;

[0071] and, optionally, a stabilizing sequence of mRNA, preferably STAB-SD, and / or a terminator sequence of the cry1Ac, Tcry1Ac gene; or

[0072] (i) a strong promoter active in the stationary phase, the strong promoter selected from the group consisting of PpapR, PpIcB, PoppA, PnprR, PnppC and PnprA, and preferably selected from the group consisting of PoppA and PnppC;

[0073] (ii) optionally, a gene sequence encoding an exportin or an anchoring protein;

[0074] (iii) the sequence of the gene encoding the target protein;

[0075] and, a stabilizing sequence for mRNA, preferably STAB-SD;

[0076] or

[0077] (i) a strong promoter active in the stationary phase, the strong promoter selected from the group consisting of PpapR, PpIcB, PoppA, PnprR, PnppC and PnprA, and preferably selected from the group consisting of PoppA and PnppC;

[0078] (ii) optionally, a gene sequence encoding an exportin or an anchoring protein;

[0079] (iii) the sequence of the gene encoding the target protein;

[0080] and, the terminator sequences of cry1Ac and Tcry1Ac genes;

[0081] Or even

[0082] (i) a strong promoter active in the stationary phase, the strong promoter selected from the group consisting of PpapR, PpIcB, PoppA, PnprR, PnppC and PnprA, and preferably selected from the group consisting of PoppA and PnppC;

[0083] (ii) optionally, a gene sequence encoding an exportin or an anchoring protein;

[0084] (iii) the sequence of the gene encoding the target protein;

[0085] Also, a stabilizing sequence of mRNA, preferably STAB-SD, and / or a terminator sequence of cry1Ac or Tcry1Ac gene.

[0086] According to other specific embodiments, the strain used is a bacterium of the genus Bacillus ΔsigE, preferably Bt ΔsigE, even more preferably Bt 407 ΔsigE, and the expression cassette comprises:

[0087] (i) a strong promoter active in stationary phase, the strong promoter being selected from PcalY and PinhA1;

[0088] (ii) optionally, a gene sequence encoding an exportin or an anchoring protein;

[0089] (iii) the sequence of the gene encoding the target protein;

[0090] and, optionally, a stabilizing sequence of mRNA, preferably STAB-SD, and / or a terminator sequence of the cry1Ac, Tcry1Ac gene;

[0091] or

[0092] (i) a strong promoter active in stationary phase, the strong promoter being selected from PcalY and PinhA1;

[0093] (ii) optionally, a gene sequence encoding an exportin or an anchoring protein;

[0094] (iii) a gene sequence encoding a target protein, preferably STAB-SD;

[0095] and, the stabilizing sequence of the mRNA;

[0096] or

[0097] (i) a strong promoter active in stationary phase, the strong promoter being selected from PcalY and PinhA1;

[0098] (ii) optionally, a gene sequence encoding an exportin or an anchoring protein;

[0099] (iii) the sequence of the gene encoding the target protein;

[0100] and, the terminator sequences of cry1Ac and Tcry1Ac genes;

[0101] Or even

[0102] (i) a strong promoter active in stationary phase, the strong promoter being selected from PcalY and PinhA1;

[0103] (ii) optionally, a gene sequence encoding an exportin or an anchoring protein;

[0104] (iii) the sequence of the gene encoding the target protein;

[0105] Also, a stabilizing sequence of mRNA, preferably STAB-SD, and / or a terminator sequence of cry1Ac or Tcry1Ac gene.

[0106] According to a specific embodiment, the protein of interest produced is an insecticidal protein of Bacillus thuringiensis.

[0107] It is known that such proteins can be used as biopesticides in formulations which conventionally comprise free insecticidal proteins in crystalline form and bacterial spores, to combat crop pests and disease vectors such as mosquitoes. In particular, these may be proteins of the Cry family (crystalline proteins) or proteins of the Cyt family (cytolytic insecticidal toxins) or Vip3 proteins (toxins active against Lepidoptera), and more preferably proteins of the Cry family.

[0108] After their expression, they are protected from degradation by the bacterial membrane constituting the envelope of the bacterial spherule. Furthermore, the non-sporulation of the bacteria gives the invention the advantage of not spreading spores in the environment.

[0109] According to another embodiment, the target protein produced can be an industrial enzyme (protease, lipase, amylase, ...) or of medical purpose. The encapsulation of such protein in bacterial spherical capsules facilitates its recovery and purification and thus reduces the production cost.

[0110] According to a third embodiment, the protein of interest produced can be a whole protein or a protein fragment capable of being used as an antigen, such as a protein from a microorganism (virus, bacteria, fungus) or a parasite.

[0111] In this embodiment, it can be advantageous to anchor the protein or fragment thereof to the surface of the bacterial balloon. This embodiment has obvious purposes for the preparation of vaccines.

[0112] Therefore, the present invention provides a bacterial platform that can be advantageously used to produce target proteins in a variety of fields, such as crop protection, disease vector control, commercial production of enzymes and the pharmaceutical industry. In addition, the technology has low cost and excellent yield, allowing large-scale production. BRIEF DESCRIPTION OF THE DRAWINGS

[0113] [ Figure 1 ]A, HD73wt strain; B, HD73ΔSpo0A strain.

[0114] [ Figure 2 ]407ΔsigE strain

[0115] [ Figure 3 ] Measurement of β-galactosidase activity in HD73wt bacteria carrying the transcriptional fusion PplcB-STAB-SD-lacZ (black curve) or the transcriptional fusion PplcB-lacZ (grey curve).

[0116] [ Figure 4 ] Measurement of R-galactosidase activity in HD73Δspo0A bacteria carrying the transcriptional fusion PpapR-STAB-SD-lacZ (grey curve) or the transcriptional fusion PoppA-STAB-SD-lacZ (black curve).

[0117] [ Figure 5 ] Measurement of β-galactosidase activity in 407ΔsigE bacteria carrying the transcriptional fusion PcalY-STAB-SD-lacZ-TermCry1Ac (black curve) or the transcriptional fusion PcalY-STAB-SD lacZ (grey curve).

[0118] [ Figure 6 ] Fluorescence measurements at different incubation times in HD73 wild-type (grey) and HD73Δspo0A (black) bacteria carrying the transcriptional fusion PpapR-STAB-SD-gfp-TermCry1Ac.

[0119] [ Figure 7 ] The toxin of interest is produced under the control of promoters PoppA and PpapR associated with the stabilizing elements STAB-SD and TermCry1Ac. Microscopic observation of strain HD73Δspo0A transformed with plasmids carrying the transcriptional fusions PoppA-STA-SD-tox1-TermCry1Ac and PpapR-STAB-SD-tox2-TermCry1Ac (A), or without the above plasmids (B). SDS-polyacrylamide gel electrophoresis of strains producing the toxin of interest (C). M, molecular weight marker. Example

[0120] 1. Effects of Creating a Non-spore-forming Phenotype on Bacterial Spherule Formation

[0121] The aspora strains correspond to the Bt HD73 wild-type strain with the Spo0A gene deleted (Bt HD73Δspo0A) or the Bt 407 wild-type strain with the sigE gene deleted (Bt 407AsigE). For both strains, the Spo0A and sigE genes were deleted by double crossover using the plasmid pMAD and the protocol described by Arnaud et al. (Arnaud et al., 2004)

[0122] The culture corresponding to the wild-type strain of Bt HD73 consisted almost entirely of spores ( Figure 1 A). In contrast, in the case of the Bt HD73Δspo0A mutant, no spores were seen ( Figure 1 B).

[0123] Bt HD73Δspo0A mutant showed bacterial spherule formation ( Figure 1 Light grey in B). Also, unlike the Bt 407 wild-type strain, the Bt 407ΔsigE strain does not form any spores and is composed of bacterial spherules ( Figure 2). Before observation under a microscope, Bt HD73 wild type and ΔspoOA strains were cultured in HCT YEG liquid medium at 30°C for 72 h. The medium consisted of HCT medium (0.7% casein hydrolysate, 0.5% tryptone, 0.68% KH2PO4, 0.012% MgSO4 7H2O, 0.00022% MnSO4 4H2O, 0.0014% ZnSO4 7H2O, 0.008% ammonium ferric citrate, 0.018% CaCl2 4H2O, pH 7.2) supplemented with 0.3% glucose and 0.05% yeast extract.

[0124] Before observation under a microscope, the Bt 407ΔsigE strain was cultured in HCT YEG liquid medium at room temperature for 96 h.

[0125] 2. Effect of the stabilizing sequence STAB-SD on the promoter activity of stationary phase genes

[0126] The inventors added an RNA stabilizing sequence STAB-SD between the PplcB promoter and the lacZ reporter gene on the plasmid pHT304-18Z-PplcB to obtain the plasmid pHT304-18-PplcB-STAB-SD-lacZ. First, the RNA stabilizing sequence STAB-SD was cloned between the XbaI and BamHI restriction enzyme sites of the vector pHT304-18. Then, the PplcB promoter was cloned upstream of the PstI and XbaI restriction enzyme sites.

[0127] The Bt HD73 wild-type strain was transformed with plasmids pHT304-18Z-PplcB and pHT304-18-PplcB-STAB SD-lacZ and then cultured in LB medium at 30°C.

[0128] LB (Luria Bertani) medium is a complex medium routinely used for bacterial strain culture, consisting of 10 g / L tryptone, 5 g / L yeast extract, and 10 g / L NaCl. The components were dissolved in 800 mL of desalted water, then the pH was adjusted to 7.0 and the volume was made to 1 L. The medium was sterilized by autoclaving at 121°C for 15 minutes.

[0129] t0 corresponds to the beginning of the transition phase between the exponential phase and the steady growth phase.

[0130] Therefore, the activity of the PplcB promoter active in stationary phase in the presence and absence of STAB-SD was compared.

[0131] Figure 3The results in show that the PplcB promoter is active in both vector constructs: in the presence and absence of STAB-SD. The presence of STAB-SD increases the expression of β-galactosidase.

[0132] 3. Stationary phase promoter activity in the ΔspoOA mutant

[0133] DNA fragments corresponding to the promoter sequences of the stationary phase genes PoppA or PpapR were synthesized and cloned into the vector pHT315. The lacZ reporter gene was cloned downstream of these sequences. The vectors were introduced into Bt HD73Δspo0A cells.

[0134] t0 corresponds to the beginning of the transition phase between the exponential phase and the steady growth phase.

[0135] Bacterial strains were cultured in HCT YEG medium at 30°C.

[0136] The β-galactosidase activity of these strains was measured during growth and it was shown that these promoters Figure 4 The times shown have strong activity, and higher activity for the PoppA promoter starts from t0.

[0137] 4 . 稳定序列T erm C ry 1A Effects of c on stationary phase gene expression

[0138] The sequence corresponding to the cry1Ac gene terminator was cloned into the downstream of the transcriptional fusion between the promoter (PcalY) of the gene expressed in stationary phase and the lacZ reporter gene on the plasmid pHT304.18Z, resulting in the plasmid pPcalY-STAB-SD-lacZ-TermCry1Ac. This vector was introduced into Bt 407ΔsigE cells.

[0139] t0 corresponds to the beginning of the transition phase between the exponential phase and the steady growth phase.

[0140] Bacterial strains were cultured in LB medium at 30°C.

[0141] The β-galactosidase activity of this strain was determined and compared with a strain carrying the same vector except for the TermCry1Ac sequence. The results showed that both plasmids allowed the expression of R-galactosidase, and the fusion carrying the TermCry1Ac sequence expressed more strongly than the fusion without TermCry1Ac ( Figure 5 ).

[0142] 5. Effects of genetic element combinations on reporter gene expression

[0143] The Bt HD73 wild-type and Bt HD73ΔspoOA strains were transformed with plasmid pHT315 carrying the transcriptional fusion PpapR-STAB-SD-gfp-TermCry1Ac to measure the activity of this transcriptional fusion in the Δspo0A genetic background and compare it with the activity of the wt strain ( Figure 6 ).

[0144] Plasmid construction was as follows. A DNA fragment corresponding to the PpapR promoter sequence followed by STAB-SD and TermCry1Ac sequences was synthesized and cloned into the vector pHT315. The gfp reporter gene was cloned downstream of this sequence.

[0145] t0 corresponds to the beginning of the transition phase between the exponential phase and the steady growth phase.

[0146] Bacterial strains were cultured in HCT YEG medium at 30°C.

[0147] The results showed that different genetic elements (plasmid, PpapR promoter, sequence STAB-SD and sequence TermCry1Ac) function in HD73Δspo0A strain. In addition, the measurement of fluorescence produced by HD73ΔspoOA and HD73 wild-type strains showed that the expression of gfp gene in Δspo0A genetic background is stronger than that in wild background.

[0148] 6. Effects of combinations of genetic elements on insecticidal protein production

[0149] The HD73Δspo0A strain was transformed with plasmids carrying PoppA-STAB-SD-crylAb-TermCry1Ac and PpapR-STAB-SD-cry1Ca-TermCry1Ac transcriptional fusions. The production of the target toxins corresponding to the Cry1Ab and Cry1Ca genes, respectively, was verified by phase contrast microscopy and SDS-polyacrylamide gel electrophoresis ( Figure 7 ). Bacteria were cultured in PEP YEGx medium at 30°C and harvested 48 h after inoculation. The medium consisted of 0.7% casein hydrolysate, 0.5% peptone, 0.68% KH2PO4, 0.012% MgSO4 7H2O, 0.00022% MnSO4 4H2O, 0.0014% ZnSO4 7H2O, 0.008% ammonium ferric citrate, 0.018% CaCl24H2O supplemented with 0.3% sugar acid and 0.05% yeast extract, pH 7.2.

[0150] The results showed that the toxin in the HD73Δspo0A bacterial spheroids carrying PoppA-STAB-SD-cry1Ab-TermCry1Ac and PpapR-STAB-SD-cry1Ca-TermCry1Ac was produced in the form of crystals, while the bacterial spheroids of the HD73Δspo0A strain without the above plasmids had no crystals ( Figure 7 B). In addition, SDS-polyacrylamide gel electrophoresis showed that the target toxin represented the majority of the bacterial spherules ( Figure 7 C).

[0151] sequence

[0152] SEQ ID NO 1—PpapR promoter region of the papR gene of Bacillus thuringiensis

[0153]

[0154] SEQ ID NO 2—PplcB promoter region of the plcB gene of Bacillus thuringiensis

[0155]

[0156] SEQ ID NO 3 - PnprA promoter region of nprA gene of Bacillus thuringiensis

[0157]

[0158] SEQ ID NO 4 - PnprA promoter region of nprA gene of Bacillus thuringiensis

[0159]

[0160] SEQ ID NO 5 - PoppA promoter region of oppA gene of Bacillus thuringiensis

[0161]

[0162] SEQ ID NO 6 - nppC gene PnppC promoter region of Bacillus thuringiensis

[0163]

[0164] SEQ ID NO 7 - promoter region of inhA1 gene PinhA1 of Bacillus thuringiensis

[0165]

[0166] SEQ ID NO 8—PcalY promoter region of the calY gene of Bacillus thuringiensis.

[0167]

[0168] The transcribed +1 is in bold. The -10 box of the promoter is underlined with a thin line. The -35 box is underlined with two lines. The DNA sequence recognized by the PlcR (PlcR) box of the PpapR and PpIcB promoters is underlined with a bold line.

[0169] SEQ ID NO 9—STAB-SD Bacillus thuringiensis

[0170] gaaaggaggg atgcc

[0171] SEQ ID NO 10-Tcry1Ac-Bacillus thuringiensis

[0172] aaactcaggt ttaaatatcg ttttcaaatc aattgtccaa gagcagcatt acaaatagat

[0173] aagtaatttg ttgtaatgaa aaacggacat cacctccatt gaaacggagt gatgtccgtt

[0174] ttactatgtt attttctagt aatacatatg tatagagcaa cttaatcaag cagagatatt

[0175] ttcacctatc gatgaaaata tctctgcttt ttcttttttt at SEQ ID NO 11 sequence contains two LysM domains as described in Shao et al., 2009, Microb Cell Fact 8, 48. doi: 10.1186 / 1475-2859-8-48.

[0176] ATGATTCAAATTGTAACGGTTCGTAGCGGTGATAGCGTATATAGCTTGGCATCAAAATATGGATCAACACC

[0177] TGACGAAATAGTAAAAGACAATGGACTAAATCCCGCTGAAACGCTCGTTGTTGGTCAGGCACTTATCGTTA

[0178] ATACGAAAGGAAATAATTATTATGTACAGCCTGGTGACAGCCTCTATCGGATTTCTCAAACATATAATGTCC

[0179] CCCTCGCTAGTTTAGCTAAAGTTAATAATTTATCTTTAAAATCTATTCTCCATGTCGGACAACAATTATATGT

[0180] ACCAAAAGGCACA

[0181] The SEQ ID NO 12 sequence contains 3 SLH domains, as described in Fedhila et al., 2006, Mol. Microbiol. 62:339-355. doi:10.1111 / j.1365-2958.2006.05362.x.

[0182] GAAGATGAGAAAACAGAAGTGGTAGAATTTAAAGATGTACCAAAGGGACATTGGTCAGAAGAAGCAATT

[0183] AATTACTTAGCGAAAGAAAAATTATTTATAGGCTATGGAAATGGTGAATTTGGATTTGGTGATAACATTACT

[0184] CGTGGACAAGTAGCACTTCTAATACAAAGATATTTAAAATTAGAAAATAATCTAGAACAAAAAACGGCATT

[0185] TACAGATACGAAAGGAAATATGTATGAAACGGCTATTGATGCAGTGGTTCAAGCTGGAATTATGACAGGC

[0186] TATGGAAATGGTATGTTCCGTCCGGATGGAGTATTAACTCGATATGAAATGTCAGTAGTACTACAAAGAGT

[0187] ATTTCAGTTAAAAGAAAATGAAAATAGTGCAGAGAATTTTAAAGATGTACCAAATGGCCATTGGGCGAAA

[0188] GGATATGTGAAAGCTTTAGTGGATAATAAATATCAAAAGGCGACGGGGAAGGGAATTTTTTAGGAGATA

[0189] ATTTCGTAACACGTGAACAATACGCACAGTTTTTGTATAATGCAATAAAGAAA

Claims

1. A non-spore-forming bacterial strain of the genus Bacillus, the bacterial strain comprising a recombinant plasmid comprising an expression cassette consisting of: (i) a strong promoter that is active in stationary phase and is regulated by a regulator selected from the group consisting of CodY, AbrB, SinR, PlcR and NprR; (ii) The sequence of the gene encoding the protein of interest.

2. The bacterial strain according to claim 1, characterized in that The strong promoter is selected from PoppA, PnppC, PinhA1, PcalY, PpapR, PpIcB, PnprR and PnprA. Preferably, the strong promoter is selected from PoppA or PnppC.

3. The bacterial strain according to claim 1 or claim 2, characterized in that The sporulation gene selected from Spo0A and sigE is inactivated by interruption or modification of the sequence, or by deletion of all or part of the gene.

4. The bacterial strain according to any one of claims 1 to 3, characterized in that: (i) the strain has a mutation in the Spo0A gene; and (ii) The strong promoter is selected from the group consisting of PpapR, PnprA, PnprR, PpIcB, PoppA and PnppC.

5. The bacterial strain according to any one of claims 1 to 3, characterized in that: (i) the strain has a mutation in the sigE gene; and (ii) The strong promoter is selected from PinhA1 and PcalY.

6. The bacterial strain according to any one of claims 1 to 5, characterized in that The expression cassette also includes a stabilizing sequence for mRNA and / or a termination sequence for the cry1Ac gene.

7. The bacterial strain according to claim 6, characterized in that The stabilizing sequence of the mRNA is the sequence STAB-SD.

8. The bacterial strain according to claims 1 to 7, characterized in that The plasmid is a plasmid selected from pHT304, pHT315 and pHT370, pHT73, pBC16, pE194, pC194 and pBM299.

9. The bacterial strain according to any one of claims 1 to 8, characterized in that The expression cassette also includes a sequence encoding an anchor sequence or export sequence for the protein.

10. The bacterial strain according to claim 1, characterized in that The bacterial strain is a strain of Bacillus thuringiensis.

11. A method for producing a target protein, the method comprising the following steps: a- preparing the bacterial strain according to any one of claims 1 to 10; b- cultivating said bacterial strain in stationary phase; and c-Optionally, purify the protein of interest.